Reported Sunday, HUTCHMED Says ORPATHYS Plus TAGRISSO Achieved Statistically Significant, Clinically Meaningful PFS And OS Improvements In MET-Driven EGFR-Mutated Lung Cancer

First global Phase III trial to show significant progression-free and overall survival benefits in this setting 

SAFFRON trial results reinforce TAGRISSO® as the backbone therapy across EGFRm lung cancer